Six‐ and Twelve‐Month Clinical Outcomes after Implantation of Prokinetic BMS in Patients with Acute Coronary Syndrome

Berlin, Tatiana; Rozenbaum, Eliezer A.; Arbel, Joel; Reges, Orna; Erel, Jacob; Shetboun, Israel; Leibovitch, M; Mosseri, Morris

doi:10.1111/j.1540-8183.2010.00550.x

Cited by 5 publications

(3 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a recent randomized trial in ACS, a new generation coated BMS achieved a 12-month MACE rate which was non-inferior to an everolimus eluting stent, combined with a slightly higher TLR rate and lower definite stent thrombosis rate (9.6% vs. 9.0%, 6.5% vs. 4.9% and 0.7% vs. 2.2%) [36]. We observed similar results in our registry (8.4%, 5.0% and 0.7%), which are also in alignment with a single center study in ACS treated with a PRO-Kinetic stent (11.1%, 2.6% and 1.8%) [37]. The PROMETHEUS study assessed the safety and efficacy of the PROKinetic stent in patients with acute ST-elevation myocardial infarction (STEMI).…”

Section: Subgroup Analysissupporting

confidence: 93%

Prospective, multi-center evaluation of a silicon carbide coated cobalt chromium bare metal stent for percutaneous coronary interventions: Two-year results of the ENERGY Registry

Erbel

Eggebrecht

Roguin

et al. 2014

Cardiovascular Revascularization Medicine

View full text Add to dashboard Cite

The population of ENERGY reflects real-world conditions with bare metal stents being mainly used in simple lesions. In this setting, percutaneous coronary intervention using a cobalt-chromium thin strut bare metal stent with a passive coating showed very good results up to 24months. (ClinicalTrials.gov:NCT01056120) SUMMARY FOR ANNOTATED TABLE OF CONTENTS: The ENERGY international registry evaluated the safety and benefits of a cobalt-chromium thin strut bare metal stent with passive coating in 1016 patients under real-world conditions until 2years. Results were encouraging with a low composite rate of cardiac death, myocardial infarction and clinically driven target lesion revascularization, even in the pre-defined high risk groups of diabetes, stents ≤2.75mm and acute coronary syndrome.

show abstract

Section: Subgroup Analysissupporting

confidence: 93%

Prospective, multi-center evaluation of a silicon carbide coated cobalt chromium bare metal stent for percutaneous coronary interventions: Two-year results of the ENERGY Registry

Erbel

Eggebrecht

Roguin

et al. 2014

Cardiovascular Revascularization Medicine

View full text Add to dashboard Cite

show abstract

“…76 A more recent study in patients with acute coronary syndrome (ACS) showed low rates for major events and re-interventions, despite the potentially higher risk of thrombosis in this group. 5 This Prokinetic stent (Biotronik) may also be benefiting from improved designs with thinner struts, compared to earlier coated devices. A drug-coated version is also available which elutes sirolimus from a biodegradable PLLA matrix.…”

Section: Non-pharmacological Stent Coatingsmentioning

confidence: 98%

Coronary Stent Materials and Coatings: A Technology and Performance Update

et al. 2015

View full text Add to dashboard Cite

This paper reviews the current state of the art for coronary stent materials and surface coatings, with an emphasis on new technologies that followed on from first-generation bare metal and drug-eluting stents. These developments have been driven mainly by the need to improve long term outcomes, including late stent thrombosis. Biodegradable drug-eluting coatings aim to address the long term effects of residual durable polymer after drug elution; the SYNERGY, BioMatrix, and Nobori stents are all promising devices in this category, with minimal polymer through the use of abluminal coatings. Textured stent surfaces have been used to attached drug directly, without polymer; the Yukon Choice and BioFreedom stents have some promising data in this category, while a hydroxyapatite textured surface has had less success. The use of drug-filled reservoirs looked promising initially but the NEVO device has experienced both technical and commercial set-backs. However this approach may eventually make it to market if trials with the Drug-Filled Stent prove to be successful. Non-pharmacological coatings such as silicon carbide, carbon, and titanium-nitride-oxide are also proving to have potential to provide better performance than BMS, without some of the longer term issues associated with DES. In terms of biological coatings, the Genous stent which promotes attachment of endothelial progenitor cells has made good progress while gene-eluting stents still have some practical challenges to overcome. Perhaps the most advancement has been in the field of biodegradable stents. The BVS PLLA device is now seeing increasing clinical use in many complex indications while magnesium stents continue to make steady advancements.

show abstract

“…As a reliable alternative, non-pharmacological solutions to address device restenosis; therefore, coating with silicon carbide, due to its semiconductor nature, demonstrates a reduction in inflammatory and thrombogenic responses [ 13 ]. The drug-coated version (sirolimus) of this technology is also available and shows significant clinical advantages [ 14 ]. The main target of this technology is the continuous protection of stents from restenosis after the drug elution and coating degradation are completed.…”

Section: Introductionmentioning

confidence: 99%

Nanodiamond Decorated PEO Oxide Coatings on NiTi Alloy

Grundsteins,

Diedkova,

Korniienko

et al. 2023

Nanomaterials

View full text Add to dashboard Cite

Cardiovascular diseases (CVDs) remain a leading cause of death in the European population, primarily attributed to atherosclerosis and subsequent complications. Although statin drugs effectively prevent atherosclerosis, they fail to reduce plaque size and vascular stenosis. Bare metal stents (BMS) have shown promise in acute coronary disease treatment but are associated with restenosis in the stent. Drug-eluting stents (DES) have improved restenosis rates but present long-term complications. To overcome these limitations, nanomaterial-based modifications of the stent surfaces have been explored. This study focuses on the incorporation of detonation nanodiamonds (NDs) into a plasma electrolytic oxidation (PEO) coating on nitinol stents to enhance their performance. The functionalized ND showed a high surface-to-volume ratio and was incorporated into the oxide layer to mimic high-density lipoproteins (HDL) for reverse cholesterol transport (RCT). We provide substantial characterization of DND, including stability in two media (acetone and water), Fourier transmission infrared spectroscopy, and nanoparticle tracking analysis. The characterization of the modified ND revealed successful functionalization and adequate suspension stability. Scanning electron microscopy with EDX demonstrated successful incorporation of DND into the ceramic layer, but the formation of a porous surface is possible only in the high-voltage PEO. The biological assessment demonstrated the biocompatibility of the decorated nitinol surface with enhanced cell adhesion and proliferation. This study presents a novel approach to improving the performance of nitinol stents using ND-based surface modifications, providing a promising avenue for cardiovascular disease.

show abstract

Six‐ and Twelve‐Month Clinical Outcomes after Implantation of Prokinetic BMS in Patients with Acute Coronary Syndrome

Abstract: Clinical outcomes at 6 and 12 months after Prokinetic stent implantation are excellent and may be attributable to its unique combination of composition, design and coating.

Cited by 5 publications

References 24 publications

Prospective, multi-center evaluation of a silicon carbide coated cobalt chromium bare metal stent for percutaneous coronary interventions: Two-year results of the ENERGY Registry

Prospective, multi-center evaluation of a silicon carbide coated cobalt chromium bare metal stent for percutaneous coronary interventions: Two-year results of the ENERGY Registry

Coronary Stent Materials and Coatings: A Technology and Performance Update

Nanodiamond Decorated PEO Oxide Coatings on NiTi Alloy

Contact Info

Product

Resources

About